Exact Sciences Drops $75M on Blood Test Like It’s Hot
In a move that screams 'We want it first or we want it all,' Exact Sciences is shelling out a whopping $75 million to snag exclusive rights to a blood-based 'liquid biopsy' from rival Freenome. Because nothing says friendly competition like locking down your neighbor's science project. To quote the deal, Exact Sciences is paying for 'exclusive rights'—so if you wanted a sneak peek at this fancy blood test, tough luck. Apparently, in the world of medical high-stakes poker, $75 million is just the ante.
Share the Story
Exact Sciences just bought a blood test like it was the last Pumpkin Spice Latte. Exclusive rights for $75M proves medicine now prefers monopolies over miracles. Thanks, capitalism!
Nothing says friendship like a $75 million handshake to keep your rival’s blood test under lock and key. Science today: where billion-dollar block parties happen in lab coats.
Exact Sciences is basically the kid who snatches the shared toy and screams 'Mine!' but with $75 million. Blood tests have never been so possessive.
Source: Statnews | Published: 8/6/2025 | Author: Jonathan Wosen
More Articles in Health
ICE Agent Did Exactly What He Was Taught, But No One Knows What That Means
Ed Sheeran Launches 2026 LOOP Tour, Tickets Not Looping Into Your Wallet
Congress Trades Shouting Match Over ICE Shooting Like A Twin Cities Soap Opera
Kennedy’s Protein-Heavy Food Pyramid: Eat More Meat, But Not Saturated Fat, Or Something
Parents Swap 'Because I Said So' For 'Oops, You Bought Too Much Junk'
America Celebrates Lower Gun Deaths While Puffing More Vape Clouds
Trump's Vaccine Makeover: Fewer Shots, More Trust, Same Measles Risks
Woman’s Epic Fight: Type 1 Diabetes vs. Ancient Mexican Ruins Timer
